2009 Pfizer Visiting Professorship in RheumatologyProgram Objective To provide opportunities for US academic institutions to host a recognized expert for 3 days of educational exchange
Program Design Up to 8 awards of $7500 each Department/division head serves as “host” of 1 visiting professor of his or her choice Three days of educational activities (eg, lectures, rounds, seminars)
Who Should Apply US medical schools and/or teaching hospitals with clear educational objectives for a proposed visit that have identified a visiting expert to meet these objectives
How to Apply Access online application at www.promisingminds.com Submit host’s and visiting professor’s curriculum vitae Submit separate statements of impact, fit, reach, and a detailed proposed agenda
Selection Process Nationally competitive Independent academic advisory board selects grant recipients
Application Deadline January 31, 2009, 11:59 PM ET
Awards Announced April 15, 2009
Dates of Visits July 1, 2009 - June 30, 2010
For questions about the programs and applications, contact: Phone: (800) 382-7075 E-mail: MAPInfo@medpt.com
New ALR Grant: Functional Genomics and Molecular Genetic Pathways in SLE The Alliance for Lupus Research (ALR) is pleased to announce that applications for the ALR’s Functional Genomics and Molecular Genetic Pathways in SLE grants are now available online. You can access the application site directly at https://proposalcentral.altum.com. Research Grants: Approved grant applications will be eligible to receive a 2-year award for up to $350,000 USD (up to $175,000 USD per year for two years). Research grants must provide evidence of preliminary data. Guidelines for application and submission are also available on the website listed above. Pilot Grants: Approved grant applications will be eligible to receive a 1-year award for up to $75,000 USD. Pilot grants are for projects that are not supported by preliminary data. Guidelines for application and submission are also available on the website listed above. Program Goals Applications submitted should focus on two principal areas: (1) functional validation to determine which candidate genes/variants identified in human lupus have an authentic role in the disease and (2) detailed elucidation of the molecular pathways modulated by these candidate genes/variants identified in human lupus. There are public resources available to facilitate functional validation of genes/variants involved in lupus. ALR encourages investigators to take advantage of all of these resources. All proposals submitted must be based on information in the public domain. Responsive applications will propose research to elucidate the functional implications of the genetic variants identified in human lupus studies. Lupus associated genes studied in animal models that are not among those also identified in human studies are not appropriate topics for this grant mechanism. ALR will focus support on: -Human Studies: Functional validation studies could use human DNA samples from henotypically well-characterized individuals to correlate a gene variant with a particular phenotype. Such human studies are particularly encouraged. · Genetic Models: Established genetic models as well as emerging genetic models can be used to look at in vivo gene/variant function. · RNA interference: RNAi depletion of candidate genes in cells, tissues or whole organisms can be used to identify phenotypes. · Imaging strategies: Imaging of cell trafficking in vivo might be useful in characterizing the impact of lupus-associated gene variants on immune responses or inflammation. · Systems-level approaches: Bioinformatic resources (i.e., interactome, gene expression, proteomic, metabolomic, and anatomical databases) can be mined to generate testable hypotheses concerning the function of candidate genes and groups of genes. · Cellular or circuit-level approaches: Studies might compare gene/variant functional consequences at the cellular and circuit levels, especially with respect to a drug challenge. · Epigenetics: Functional validations of epigenetic mechanisms of gene regulation in the context of lupus, including potential maternal and paternal imprinting or X chromosome inactivation, are of interest. Amounts Research Grant: This grant mechanism provides up to $350,000 USD for two years ($175,000 per year for two years of support) and is not renewable. Proposals for less than the maximum amount are encouraged. The ALR limits indirect costs to 8 percent of direct costs excluding equipment. Pilot Grant: This grant mechanism provides up to $75,000 USD for one year of support and is not renewable. Proposals for less than the maximum amount are encouraged. Principal Investigator salaries are not supported for Pilot Grants. Salary requests may be made for technical assistance, graduate students and postdoctoral fellows. The ALR limits indirect costs to 8 percent of direct costs excluding equipment. Application Requirements Applications are open to investigators working at established research institutions (both for profit and not-for profit) as well as investigators at state health agencies, the FDA, VA and at intramural divisions of NIH. Applications may be submitted by investigators working anywhere in the world. Non-U.S. applicants whose projects involve human subjects must work at institutions that have human subjects committees that operate in a substantially similar manner to a U.S. Institutional Review Board. If you have any questions or require any additional information regarding the application process, please contact Diomaris Gonzalez, Manager of Research Administration at (212) 218-2840, 800-867-1743 or dgonzalez@lupusresearch.org.
APPLICATION DUE DATE – February 16th, 2009
Applications for SSF Research Grants
SSF offers research grants in the amount of $35,000 annually for two years, the second year being dependent on satisfactory grant progress. In 2007, four $35,000 Research Grants were awarded. All SSF research grants are open to basic and clinical scientists holding an advanced degree (MD, DDS, DMD, or PhD) at any U.S. university or research institution. Both junior and senior investigators may apply. For physicians, advanced clinical training in a specialty related to Sjögren's syndrome, such as rheumatology or ophthalmology, is desirable. The application receipt deadline is February 1 each year. The grant funding period is July 1 through June 30.
Sjögren's Syndrome Foundation 6707 Democracy Boulevard Suite 325 Bethesda, MD 20817 Toll Free: (800) 475-6473 Local call: (301) 530-4420 Fax: (301) 530-4415
Established Investigator Grant
Purpose: The Scleroderma Foundation is seeking applications from promising established investigators both inside and outside the field of SSc research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to SSc. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources. Eligibility Requirements: Applications may be submitted by domestic non-profit organizations, public and private such as universities, colleges, hospitals and laboratories. Foreign organizations and institutions are eligible. Applicants must have a doctorate degree in Medicine, Osteopathy, Veterinary Medicine or one of the sciences, must have completed a postdoctoral fellowship, have been Principal Investigator on grants from the Scleroderma Foundation or other national, private or government agencies in the past. Investigators who have questions about eligibility should contact the Scleroderma Foundation (see below). Mechanism of Support: Applicants may request up to $75,000 (Up to 8% of the Direct Costs per year of award may be set aside as indirect costs. The indirect cost amount will be subtracted from the yearly total [up to $75,000) of the award) per year for up to two years (total for 2 years not to exceed $150,000). These awards are not renewable. Before completion of this grant, investigators are encouraged to seek more substantial continuing support for research through other grant mechanisms through private or government agencies. Replacement of the Principal Investigator on this award is not permitted. There will be no routine escalation for future years. Awards are contingent on the availability of funds and the receipt of sufficiently meritorious applications meeting the stated eligibility requirements. Research Objectives: The Scleroderma Foundation Innovative Grant is designed to facilitate highly innovative or highly relevant and meritorious pilot projects by established investigators in areas of research related to SSc that will culminate in more substantial funding from Federal or non-federal granting agencies such as the National Institutes of Health, National Science Foundation and the Department of Defense or Veterans Affairs.
Deadline: Sept. 15, 2009 by 5 p.m. ET.
Attention: Research Grant Manager Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923 Phone: 978-463-5843 Fax: 978-463-5809 Email: sfinfo@scleroderma.org
New Investigator Grant
Purpose: The Scleroderma Foundation is seeking applications from promising new investigators who hold faculty or equivalent positions and who wish to pursue a career in research related to systemic sclerosis (SSc, scleroderma). This grant will support promising research that is likely to lead to individual research project grants. Eligibility Requirements: Applications may be submitted by domestic non-profit organizations, public and private such as universities, colleges, hospitals and laboratories. Foreign organizations and institutions are not eligible. These new investigator grants may not be used to support thesis or dissertation research or fellowship training. Applicants must have a doctoral degree in Medicine, Osteopathy, Veterinary Medicine or one of the sciences and must have completed a postdoctoral fellowship by the grant award date. Applicants who have been a Principal Investigator on grants from the Scleroderma Foundation or other national, private or government agencies other than fellowship grants are not eligible for this award. Investigators who have questions about eligibility should contact the Scleroderma Foundation (see below). Mechanism of Support: Applicants may request up to $50,000 (Up to 8% of the Direct Costs per year of award may be set aside as indirect costs. The indirect costs will be subtracted from the yearly total (up to $50,000) of the award.) per year for up to three years (total for three years not to exceed $150,000). These awards are not renewable. Before completion of this grant, investigators are encouraged to seek continuing support for research through other grant mechanisms through private or government agencies. Replacement of the Principal Investigator on this award is not permitted. There will be no routine escalation for future years. Awards are contingent on the availability of funds and the receipt of sufficiently meritorious applications meeting the stated eligibility requirements. Research Objectives: The Scleroderma Foundation New Investigator Grant is designed to facilitate the entry of promising new investigators into areas of research related to SSc.
Grant Application Deadline: Sept. 15, 2009 by 5 p.m. ET.
Grants Prorgam
Grant Deadline is January 15, 2009
The Arthritis National Research Foundation (ANRF) is dedicated to funding highly qualified investigators associated with major research institutes, universities and hospitals throughout the country who are seeking to discover new knowledge for the prevention, treatment and cure of arthritis and other rheumatic diseases. ANRF's Board of Directors and Scientific Advisory Board are committed to providing uninterrupted research in the search for new therapies and a cure. The results will mean improved treatment for the 66 million Americans who suffer from some form of arthritis. The Scientific Advisory Board and the Board of Directors review grant proposals annually. Clinical and basic studies will be considered. Clinical studies should have a translational component that helps reveal the underlying mechanisms or response to therapy. Priority will be given to investigators possessing either a M.D. and/or Ph.D. degree or equivalent, affiliated with a qualified, non-profit institution. Preference will be given to senior post-doctoral investigators transitioning to independent investigator status and new assistant professors. Applicant may not have (or ever had) an NIH R01 grant or equivalent. Grants are awarded for one year. First-year recipients may submit a detailed progress report by mid-January during the year of their award, requesting a second year. See guidelines for details. NEW FUNDING LEVEL Grants awarded will be in the range of $20,000 to $75,000. Partial funding may be awarded if grantee has documentation that the remainder of the funding for proposed research has been acquired.
The Foundation will fund salaries, supplies and equipment directly related to the proposed studies. Overhead or indirect costs will not be funded. The Foundation will seek to fund at least one grant each year focusing on juvenile arthritis. ANRF routinely funds 8-15 grants per year. Applications not in strict compliance with stated policies and guidelines will be subject to administrative inactivation. Additional administrative review may be rendered to determine priority for funding when multiple proposals are received from a single laboratory, Division or Department. No-Cost Time Extensions on ANRF Grant Awards No-cost extensions may be approved for ANRF grant awards, not to exceed three months. Requests from current grant recipients must be submitted in writing (e-mail acceptable). Transfer of ANRF Grant Awards If an investigator changes institutions during the grant award period, the ANRF requests the following: 1) A letter from the new institution, preferably the head of the department, stating that the investigator will be working on the same project and have the laboratory facilities and time available to do so. The letter should indicate the start date of the investigator in the new environment, as well as the contact information, address, e-mail, phone for disbursement of the remaining ANRF grant funds. The letter must be co-signed by the responsible business/grants management official of the new institution. 2) The original institution is responsible for sending any unused funds, prorated depending on the date, to the ANRF. We will then forward a new check for the unused funds to the new institution.
Arthritis National Research Foundation 200 Oceangate, Suite 830 Long Beach, CA 90802 Tel: 1-800-588-2873 Fax: 562-983-1410 anrf@ix.netcom.com
Within Our Reach Rheumatoid Arthritis Grants
Application Deadline The application deadline is December 1, 2008. Applicants are responsible for submitting all required documents prior to this deadline. If you have questions or need assistance, please contact the REF office by e-mail or by phone at (404) 633-3777. For more information about this award, please contact the REF office by e-mail or by phone at (404) 633-3777.
American College of RheumatologyResearch and Education Foundation 1800 Century Place Suite 250 Atlanta, GA 30345
1
